Connect with us
AstraZeneca will present over 85 abstracts at ASCO 2026, showcasing late-stage data across multiple cancers and a rare hematological disease. Highlights include trials in liver, breast,...
The FDA approved Hepcludex (bulevirtide-gmod), the first treatment for chronic hepatitis delta virus (HDV) in adults with or without compensated cirrhosis. Clinical trials showed significantly higher...
Roche Pharma invested €57 million in Spain in 2025, running 283 clinical trials on 76 molecules with 8,584 patients and 950 researchers across 178 centers. Trials...
Asabys Partners has launched Asabys Innvierte Tech Transfer, a venture capital fund of up to €120 million focused on early-stage life sciences and deep tech companies...
Researchers at McMaster University identified the uPAR receptor as a key marker in glioblastoma tumor-initiating cells. Published in Science Translational Medicine, their study showed that targeting...
Novo Nordisk has transferred its discontinued Parkinson’s therapy to AI biotech startup Cellular Intelligence, retaining equity and milestone rights instead of making a traditional sale. The...
IgA nephropathy, a rare autoimmune disease often leading to kidney failure, previously lacked targeted treatments, relying on supportive care with limited effectiveness. The new drug esparsentan...
The inflammatory bowel disease market is rapidly growing, driven by unmet patient needs despite existing therapies. Major pharma acquisitions highlight strong demand for innovative treatments. Abivax’s...
Biotech news this week highlights sharp contrasts: Redcare Pharmacy posted strong growth and profitability, while Ocugen faced rising costs despite higher revenue but secured $115 million...
At Swiss Biotech Day in Basel, early discussions lacked data, revealing mixed sentiment despite official reports showing strong growth. Switzerland’s biotech sector reached record revenues, stable...
 |
|
 |  |
 |
|